NCT06780670: Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 443 planned
- Started
- 27 Feb 2025
- Primary completion
- 27 Jun 2028
- Arms
- Phase II: AAA817 Dose B, Phase II: AAA817 Dose A, Phase III: Recommended Phase 3 Dose of AAA817
- Results
- None posted
- 17 Jan 2025: Trial registered
- 27 Feb 2025: Trial started